We believe that biosimilars are the future of affordable healthcare. Our unique protein production platform and bioanalytic approach allows us to produce quality biosimilar products efficiently and effectively to increase patient access at a lower cost.
Additionally, we are one of the only companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This focus allows us to ensure a robust pipeline of high-quality therapeutics, which will ensure we can expand access to life-changing biologics to more patients.
We have an established expertise in the development of biosimilars, and our partnership with Hospira validates our approach to increase access to lower-cost, high-quality biologic drugs.
Learn more about the potential cost savings and safety of these innovative products here.